Management

Pega-One engaged Biotech Value Advisors (BVA) to manage the daily operations. BVA is a valued partner for pre-commercial biotech companies looking to develop and commercialize innovative medicines. The BVA leadership team has decades of experience in product development and commercialization and has a broad network of subject matter experts to provide additional Clinical Development, CMC and Regulatory support when needed. 

Chris Stijnen is the Chief Operating Officer at Pega-One. Over the course of his 30-year career in the pharmaceutical industry, Chris successfully launched new products in various markets, managed local operations for Organon and Bristol Myers Squibb in Asia and Europe and supported the launch of Opdivo in China as VP Portfolio Strategy.